Literature DB >> 25912004

Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?

Chan Yoon Cheah1, John F Seymour.   

Abstract

Secondary central nervous system (CNS) progression in patients with non-Hodgkin lymphoma (NHL) is associated with a particularly poor prognosis. In this review, we summarize and critically evaluate the current literature to guide the practicing clinician in estimating CNS relapse risk in order to select individual patients who may benefit from CNS prophylaxis, covering histologic subtype, anatomic location, and molecular and clinical factors. We summarize the data regarding different prophylaxis strategies used and provide our recommendation regarding who should receive it, what they should receive, and when it should be administered.

Entities:  

Mesh：

Year:  2015        PMID： 25912004     DOI： 10.1007/s11912-015-0450-4

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  94 in total

1.  B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Authors:  Matija Snuderl; Olga K Kolman; Yi-Bin Chen; Jessie J Hsu; Adam M Ackerman; Paola Dal Cin; Judith A Ferry; Nancy Lee Harris; Robert P Hasserjian; Lawrence R Zukerberg; Jeremy S Abramson; Ephraim P Hochberg; Hang Lee; Alfred I Lee; Christiana E Toomey; Aliyah R Sohani
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

2.  Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting.

Authors:  Maurilio Ponzoni; Andrés J M Ferreri; Elías Campo; Fabio Facchetti; Luca Mazzucchelli; Tadashi Yoshino; Takuhei Murase; Stefano A Pileri; Claudio Doglioni; Emanuele Zucca; Franco Cavalli; Shigeo Nakamura
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

3.  First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.

Authors:  Umberto Vitolo; Annalisa Chiappella; Andrés J M Ferreri; Maurizio Martelli; Ileana Baldi; Monica Balzarotti; Chiara Bottelli; Annarita Conconi; Henry Gomez; Armando Lopez-Guillermo; Giovanni Martinelli; Francesco Merli; Domenico Novero; Lorella Orsucci; Vincenzo Pavone; Umberto Ricardi; Sergio Storti; Mary K Gospodarowicz; Franco Cavalli; Andreas H Sarris; Emanuele Zucca
Journal:  J Clin Oncol       Date:  2011-06-06       Impact factor: 44.544

4.  Survival Outcomes of Primary Intraocular Lymphoma: A Single-institution Experience.

Authors:  Michelle M Kim; Bouthaina S Dabaja; Jeffrey Medeiros; Stella Kim; Pamela Allen; Patricia Chevez-Barrios; Dan S Gombos; Nathan Fowler
Journal:  Am J Clin Oncol       Date:  2016-04       Impact factor: 2.339

5.  Central nervous system involvement in diffuse large B-cell lymphoma.

Authors:  Wataru Yamamoto; Naoto Tomita; Reina Watanabe; Yukako Hattori; Yuki Nakajima; Rie Hyo; Chizuko Hashimoto; Shigeki Motomura; Yoshiaki Ishigatsubo
Journal:  Eur J Haematol       Date:  2010-03-03       Impact factor: 2.997

6.  The intracerebral penetration of intraventricularly administered methotrexate: a quantitative autoradiographic study.

Authors:  S A Grossman; C S Reinhard; H L Loats
Journal:  J Neurooncol       Date:  1989-11       Impact factor: 4.130

7.  Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.

Authors:  Naoto Tomita; Fumio Kodama; Heiwa Kanamori; Shigeki Motomura; Yoshiaki Ishigatsubo
Journal:  Cancer       Date:  2002-08-01       Impact factor: 6.860

Review 8.  Emerging pathways in the development of AIDS-related lymphomas.

Authors:  Antonino Carbone
Journal:  Lancet Oncol       Date:  2003-01       Impact factor: 41.316

9.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

10.  Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group.

Authors:  E Zucca; A Conconi; T I Mughal; A H Sarris; J F Seymour; U Vitolo; R Klasa; M Ozsahin; G M Mead; M A Gianni; S Cortelazzo; A J M Ferreri; A Ambrosetti; M Martelli; C Thiéblemont; H Gomez Moreno; G Pinotti; G Martinelli; R Mozzana; S Grisanti; M Provencio; M Balzarotti; F Laveder; G Oltean; V Callea; P Roy; F Cavalli; M K Gospodarowicz
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544
View more
  4 in total

Review 1.  Central Nervous System Involvement in Peripheral T Cell Lymphoma.

Authors:  Dai Chihara; Yasuhiro Oki
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 3.952

2.  Multifocal extranodal lymphoma: A case report.

Authors:  Chao Li; Lin Li; Ping Zhang; Jin-Song Zhang; Ting Gao; Yan Xu; Wen-Chan Li
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

3.  Lenalidomide and Temozolomide Combination in a Very Elderly Patient with CNS Relapse of Diffuse Large B-Cell Lymphoma.

Authors:  Emanuele Cencini; Alberto Fabbri; Umberto Arrigucci; Alfonso Cerase; Monica Bocchia
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-06-16       Impact factor: 2.576

4.  The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.

Authors:  Dai Chihara; Michelle A Fanale; Roberto N Miranda; Mansoor Noorani; Jason R Westin; Loretta J Nastoupil; Fredrick B Hagemeister; Luis E Fayad; Jorge E Romaguera; Felipe Samaniego; Francesco Turturro; Hun J Lee; Sattva S Neelapu; M Alma Rodriguez; Michael Wang; Nathan H Fowler; Richard E Davis; L Jeffrey Medeiros; Yasuhiro Oki
Journal:  PLoS One       Date:  2018-03-14       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.